Ocular adverse effects of bladder medication: a systematic review

References

• Kuchel G, Smith P, Wolff G. Overactive bladder in the vulnerable elderly. Res Rep Urol 2014;6:131.
   PubMedGoogle Scholar
• Abreu-Mendes P, Pinto R, Oliveira PD. Systemic therapy for bladder pain syndrome/interstitial cystitis (BPS/IC): systematic review of published trials in the last 5 years. Curr Bladder Dysfunct Rep 2020;15:192–202.
   Google Scholar
• Sekeroglu MA, Hekimoglu E, Tasci Y, et al. Ocular surface changes following oral anticholinergic use for overactive bladder. Cutan Ocul Toxicol 2015;35:218–221.
   PubMedGoogle Scholar
• DuBeau CE, Kuchel GA, Johnson T, 2nd, et al. Fourth International Consultation on Incontinence Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence. Neurourol Urodyn 2010;29:165–178.
   PubMed Web of Science ®Google Scholar
• Macdiarmid SA, Sand PK. Diagnosis of interstitial cystitis/painful bladder syndrome in patients with overactive bladder symptoms. Rev Urol 2007; 9:9–16.
   PubMedGoogle Scholar
• Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol 2018;11:117–125.
   PubMedGoogle Scholar
• Lopez SR, Mangır N. Current standard of care in treatment of bladder pain syndrome/interstitial cystitis. Ther Adv Urol 2021;13:17562872211022478.
   Google Scholar
• Manaviat MR, Rashidi M, Afkhami-Ardekani M, Shoja MR. Prevalence of dry eye syndrome and diabetic retinopathy in type 2 diabetic patients. BMC Ophthalmol 2008;8:10.
   PubMed Web of Science ®Google Scholar
• Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Methodological Resources | Systematic review and literature review software by evidence partners. n.d. Available from: https://www.evidencepartners.com/resources/methodological-resources/ [last accessed 20 May 2020].
   Google Scholar
• Alton-Yaycioglu R, Yaycioglu O, Akova Y, et al. 481Ocular side effects of tolterodine and oxybutynin: a single-blind prospective randomized trial. Eur Urol Suppl 2005;4:123.
   Google Scholar
• Chapple CR, Amarenco G, Aramburu MAL, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn 2013;32:1116–1122.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J 2013;24:1447–1458.
   PubMed Web of Science ®Google Scholar
• Chu F, Smith N, Uchida T. Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Curr Ther Res 2009;70:405–420.
   PubMedGoogle Scholar
• Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006;67:275–280.
   PubMed Web of Science ®Google Scholar
• Digesu GA, Verdi E, Cardozo L, et al. Phase IIb, Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity. Urology 2012;80:48–54.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Maanen RV, Chapple C, et al. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). Eur Urol 2018;74:501–509.
   PubMed Web of Science ®Google Scholar
• Haab F, Cardozo L, Chapple C, Ridder A. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376–384.
   PubMed Web of Science ®Google Scholar
• Higgins K, Welch RJ, Bacorn C, et al. Identification of patients with pentosan polysulfate sodium-associated maculopathy through screening of the electronic medical record at an academic center. J Ophthalmol 2020;2020:8866961.
   PubMedGoogle Scholar
• Hsiao S-M, Lin H-H, Kuo H-C. Treatment outcome of overactive bladder patients receiving antimuscarinic therapy for more than one year. Low Urin Tract Symptoms 2016;10:21–26.
   PubMedGoogle Scholar
• Ismael AAA, Saleh HH. Efficacy and safety of mirabegron in treatment of overactive bladder (Dose range study). Ind J Publ Health Rese Dev 2018;9:379.
   Google Scholar
• Jünemann K-P, Halaska M, Rittstein T, et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 2005;48:478–482.
   PubMed Web of Science ®Google Scholar
• Marschall-Kehrel D, Feustel C, Geeter CPD, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Eur Urol 2009;55:729–738.
   PubMedGoogle Scholar
• Martínez-García R, Abadías M, Arañó P, et al. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study. Eur Urol 2009;56:184–192.
   PubMed Web of Science ®Google Scholar
• Novack GD, Lewis RA, Vogel R, et al. Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther 2013;29:674–680.
   PubMed Web of Science ®Google Scholar
• Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. Ophthalmology 2018;125:1793–1802.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Fine HF, Vora R. From bladder pain to blurry vision: pentosan polysulfate sodium and the development of a novel maculopathy. Ophthalmic Surg Lasers Imaging Retina 2020;51:674–677.
   PubMedGoogle Scholar
• Sand PK, Steers WD, Dmochowski R, et al. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:667–675.
   PubMed Web of Science ®Google Scholar
• Swift SE, Siami P, Forero-Schwanhaeuser S. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment. Clin Drug Invest 2009;29:305–316.
   PubMedGoogle Scholar
• Wagg A, Dale M, Tretter R, et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013;64:74–81.
   PubMed Web of Science ®Google Scholar
• Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311–2315.
   PubMed Web of Science ®Google Scholar
• A study to find out how fesoterodine works in children aged 6 to 17 years with bladder overactivity caused by a neurological condition - full text view. March 19, 2012. Full Text View - https://ClinicalTrials.gov.
   Google Scholar